Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases

Michael Benatar, Joanne Wuu, Caroline McHutchison, Ronald B. Postuma, Bradley F. Boeve, Ronald Petersen, Christopher A. Ross, Howard Rosen, Jalayne J. Arias, Stephanie Fradette, Michael P. McDermott, Jeremy Shefner, Christine Stanislaw, Sharon Abrahams, Stephanie Cosentino, Peter M. Andersen, Richard S. Finkel, Volkan Granit, Anne Laure Grignon, Jonathan D. RohrerCorey T. McMillan, Murray Grossman, Ammar Al-Chalabi, Martin R. Turner, Peter M. Andersen, Jalayne Arias, Michael Benatar, Bradley Boeve, Stephanie Cosentino, Kuldip Dave, Toby Ferguson, Mary Kay Floeter, Jonathan Rohrer, Stephanie Fradette, Tania Gendron, Volkan Granit, Anne Laure Grignon, Murray Grossman, Amelie Gubitz, Petra Kaufman, Isabelle Le Ber, Suzee Lee, Andrea Malaspina, Michael P. McDermott, Caroline McHutchison, Corey McMillan, Katie Nicholson, Ronald Petersen, Richard Robinson, Howard Rosen, Christopher Ross, Jeremy Shefner, Christine Stanislaw, Nadine Tatton, Neil Thakur, Jochen Weishaupt, Joanne Wuu

Research output: Contribution to journalReview articlepeer-review


Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer's disease based on inferred underlying histopathology. Parkinson's disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington's disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned - more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers - we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.

Original languageEnglish (US)
Pages (from-to)27-44
Number of pages18
Issue number1
StatePublished - Jan 1 2022


  • amyotrophic lateral sclerosis (ALS)
  • disease prevention
  • neurodegeneration
  • pre-symptomatic

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this